What Mylan-Trazodone Treats: Main Uses and Benefits

Mylan-Trazodone is commonly used across therapeutic domains involving distressing symptoms that interfere with daily functioning. The medication is primarily applied in the management of Major Depressive Disorder. It is also frequently utilized for addressing associated symptom clusters, including sleep disturbances and pronounced anxiety or agitation. The therapeutic benefit focuses on helping patients cope more steadily with difficult episodes.

---

Quick Fact: Relief for Sleep and Mood

The medication assists with managing the core symptoms of low mood and lack of energy, while also being relevant for managing chronic difficulty falling asleep and reducing nighttime awakenings. This combination of effects contributes to improved comfort during symptomatic periods.

In complex clinical settings, the medication is considered relevant as a therapeutic option for specialized use in geriatric patients with co-existing neurocognitive disorders, supporting their general comfort and assisting with maintaining functional stability during periods of heightened symptoms.

Regulatory References

1. NIH MedlinePlus Drug Information

Mylan-Trazodone (Trazodone hydrochloride) is an antidepressant approved for use in adults for the treatment of Major Depressive Disorder. Its use is strictly defined by regulatory eligibility criteria and contraindications.

Contraindications and Non-Recommended Use

Classification	Rule (Official Regulatory Status)
Absolute Prohibition	Patients taking or within 14 days of stopping a Monoamine Oxidase Inhibitor (MAOI), including intravenous methylene blue.
Absolute Prohibition	Known hypersensitivity or allergy to Trazodone or its components.
Non-Recommended Use	The initial recovery phase following a myocardial infarction (heart attack).

Age and Condition-Based Restrictions

• Pediatric Patients (Under 18): Use is not approved because safety and effectiveness have not been established by regulators.
• Geriatric Patients (Older Adults): Use requires caution and close monitoring due to increased potential for adverse effects, such as low sodium levels.
• Organ Impairment: Use with caution in patients with renal (kidney) or hepatic (liver) impairment, as comprehensive safety data for these populations are not fully established.
• Pregnancy and Lactation: Use during pregnancy requires a formal assessment where the benefit must outweigh the risk; newborns should be monitored for withdrawal. Trazodone is excreted into breast milk, requiring a decision to discontinue the drug or breastfeeding.

Mylan-Trazodone has documented interactions with several classes of medicines and substances, primarily due to its metabolic pathway and pharmacodynamic effects, as outlined in official regulatory documents.

Contraindicated Combinations

Concomitant use with Monoamine Oxidase Inhibitors (MAOIs), including certain agents like linezolid or intravenous methylene blue, is contraindicated due to the serious risk of developing Serotonin Syndrome. At least 14 days must separate the discontinuation of one drug and the initiation of the other.

Pharmacokinetic and Exposure Interactions

Mylan-Trazodone is metabolized primarily by the CYP3A4 enzyme. Co-administration with strong CYP3A4 inhibitors (e.g., ritonavir, ketoconazole) significantly increases Trazodone plasma concentration/exposure. Conversely, strong CYP3A4 inducers (e.g., carbamazepine) decrease Trazodone exposure.

Pharmacodynamic Interactions

• Serotonergic Agents: Combining Trazodone with other serotonergic drugs (e.g., SSRIs, triptans, tramadol, St. John’s Wort) increases the risk of Serotonin Syndrome.
• CNS Depressants: Trazodone may enhance the effects of alcohol, barbiturates, and other CNS depressants, increasing the risk of sedation and central nervous system impairment.
• Cardiac Effects: Trazodone is known to prolong the QTc interval. Concomitant use with other drugs that also prolong the QTc interval is strongly cautioned due to the heightened risk of cardiac arrhythmias.
• Anticoagulants/Antiplatelets: Co-administration with agents that interfere with coagulation, such as warfarin, NSAIDs, or aspirin, may increase the risk of abnormal bleeding.

Dual-Action Modulation of Neurotransmitter Systems

Mylan-Trazodone is a modulator with multiple distinct targets that acts through two primary domains to influence the central nervous system. The first domain involves high-affinity antagonism (blocking) of key receptors—specifically the Serotonin 5- HT2A, Histamine H1, and Alpha-1 (alpha1) adrenergic receptors. This action rapidly suppresses central signaling pathways linked to physiological alertness and sympathetic tone. The second domain, which engages at higher concentrations, involves inhibition of the Serotonin Transporter ( SERT), an action associated with lower binding affinity, which promotes the sustained presence of serotonin in the synapse.

---

The Mechanism's Multi-Layered Action

The mechanism's effect is fundamentally dose-dependent and operates in layered cascades. The rapid blockade of the high-affinity 5- HT2A, H1, and alpha1 receptors immediately suppresses the input to arousal centers, leading to the rapid suppression of central arousal. In contrast, the sustained modulation of serotonin levels via SERT inhibition and 5- HT1A partial agonism results in a sustained alteration of synaptic serotonin concentration, influencing long-term neurochemical activity. The active metabolite m-CPP also contributes to the net effect by engaging its own 5- HT receptor activity. This distinct combination of actions results in immediate suppression of over-arousal pathways and gradual systemic neurochemical change.

Mylan-Trazodone is administered exclusively via the oral route as either an Immediate-Release (IR) or Extended-Release (ER) tablet formulation, with specific instructions dependent on the form. The starting dose for adults is typically 150 mg per day, which is generally administered in divided doses for the IR formulation. Dosage adjustments may be made in increments of 50 mg every three to four days up to a maximum outpatient dose of 400 mg per day.

A critical distinction in administration is the relationship with food: the IR tablet is directed to be taken shortly after a meal or a light snack, whereas the ER tablet is directed to be taken on an empty stomach and is scheduled for once-daily use. The IR dosing schedule often includes administering a larger portion of the total daily amount at bedtime.

For older or frail adults, the starting dose is lower, beginning at 100 mg per day in divided doses, with the maximum dose generally not exceeding 300 mg daily. The duration of use is typically for several months following initial response, and discontinuation requires a gradual dose reduction (tapering) protocol. Furthermore, extended-release tablets must not be crushed or chewed to maintain their intended release profile.

Research Evidence / Overview of Studies for Mylan-Trazodone

Evidence for use in Major Depressive Disorder (MDD)

Mylan-Trazodone research explored its use in individuals with Major Depressive Disorder (MDD), a condition marked by functional limitations and periods of heightened symptoms. The research primarily was observed in short-term randomized controlled trials (RCTs) and small pilot studies. These studies were used in research exploring how symptoms change over time, focusing on changes measured by standard clinical assessments of mood and specific outcomes reflecting daily functioning or activity level.

The findings describe patterns observed in the studies over the short follow-up periods, highlighting changes measured in mood assessment scores. Some trials report how symptoms evolved in the observed populations, describing patterns observed in relation to outcomes reflecting systemic or functional imbalance. However, the findings were mixed across different studies, and the evidence remains limited due to the focus on short follow-up durations. The data show patterns related to symptom intensity, but these results apply only to the populations studied and do not offer individual predictions.

---

Evidence for associated Insomnia symptoms

Research involving Mylan-Trazodone explored its evaluation in studies relevant in trials assessing short-term or episodic symptom patterns, specifically focusing on insomnia that may be associated with MDD or other conditions involving periods of heightened symptoms. The studies monitored outcomes related to systemic or functional imbalance, specifically focusing on sleep parameters such as duration and subjective reports of quality.

Findings help contextualize how patients reported their experience, with some participants describing patterns related to patient-reported outcomes describing perceived discomfort. The consistency of these observations beyond the narrow setting of short-term studies is not fully established. Follow-up durations were limited, and the research has generally focused on outcomes describing episodic or acute changes in sleep, not chronic, long-lasting conditions.

---

What is still uncertain about Mylan-Trazodone

The primary limitation is that long-term effects are not fully established because follow-up durations were limited in most key studies. Comparative evidence is lacking against many non-pharmacological or alternative interventions. Data for certain groups remain insufficient, especially for adolescents and those with complex medical comorbidities. The available research highlights what is known — and what is still uncertain — stressing that study results reflect the specific conditions under which they were conducted.

Key Studies & References

1. Extended-release Trazodone in Major Depressive Disorder: A Randomized, Double-blind, Placebo-controlled Study
2. The efficacy and safety of trazodone for sleep problems in depressive patients: a GRADE-assessed systematic review and meta-analysis of clinical trials
3. Label: TRAZODONE HYDROCHLORIDE tablet (FDA Regulatory Document)
4. Depression in adults: treatment and management (NICE Guideline NG222)

Official Storage and Disposal Requirements

Regulatory agencies define specific requirements for storing and disposing of Trazodone Hydrochloride to maintain its stability and ensure public safety.

Storage Conditions

Requirement	Specification
Temperature	Store at controlled room temperature (e.g., 20°C to 25°C).
Protection	Keep in the original, tightly closed container, away from moisture, excessive heat, and direct light.
Handling	Do not freeze. Keep the medication out of the reach of children.

Disposal Instructions

Official disposal protocols prioritize the use of an approved drug take-back program or mail-back service for unused or expired tablets. If take-back options are unavailable, the medicine should be mixed with an undesirable substance, such as coffee grounds or dirt, and sealed in a container before being discarded with the household trash. Trazodone is generally not recommended for flushing down the sink or toilet.